Avenzo gets FDA permission to proceed with Phase I/II trials of an EGFR/HER3 bispecific antibody and a CDK4 inhibitor in select solid tumors.

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

Located at the system's hospital in St. George, Utah, the clinic intends to offer T-cell collection closer to home.

The Itovebi, Ibrance, and fulvestrant combination demonstrated improved survival outcomes versus placebo in a Phase III trial.

In trials, the drug has been effective in some tumors, but researchers at the University of Turku in Finland hope to identify biomarkers to better select patients.

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

Multiple first-in-human trials showed functional and biomarker improvements in early data reported at ASGCT's annual meeting.

NEW YORK – CureDuchenne Ventures has made a $1 million initial investment in Entos Pharmaceuticals, supporting its development of a genetic medicine for Duchenne muscular dystrophy (DMD).

Investigators presented interim data from a Phase III trial of Lenmeldy in patients with the late juvenile form of disease at ...

NEW YORK – The first patient with an advanced, MTAP-deleted solid tumor has received Tango Therapeutics' PRMT5 inhibitor TNG456 in a Phase I/II trial, the company said Wednesday. The Boston-based firm ...

The treatment has been used in a trial to treat children with GM1 gangliosidosis, but if the FDA allows, this would be the ...

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.